A risk-benefit analysis in research is the structured evaluation that weighs a study’s potential harms to participants against the benefits the study is expected to produce, and it is the central judgment an Institutional Review Board (IRB) makes before any human subjects research can begin. Under federal regulations, no covered study can enroll participants until the board confirms the risks have been minimized and are reasonable in relation to anticipated benefits, both to participants and in the knowledge the research is expected to generate.1eCFR. 45 CFR 46.111 – Criteria for IRB Approval of Research
What Counts as a Risk and What Counts as a Benefit
Risks in research fall into five broad categories. Physical risks include side effects from an experimental drug or discomfort from a medical procedure. Psychological risks cover emotional distress from sensitive questions or stressful experimental conditions. Social and legal risks arise when participation could expose private information that damages a person’s reputation, relationships, or legal standing. Economic risks include lost wages, travel costs, or other financial burdens the study imposes.
For each identified risk, researchers evaluate two dimensions: the probability that the harm will actually occur, and the magnitude of the harm if it does. A study might carry a low probability of a severe outcome, like a rare allergic reaction to an experimental drug, or a high probability of a mild one, like temporary soreness from a blood draw. Both matter, and the IRB weighs each combination differently. Estimates should draw on published literature, animal studies, and pilot data rather than vague labels like “low risk” without supporting evidence.
On the benefit side, the analysis distinguishes between direct advantages to the participant and broader value for society. A direct benefit might be access to an experimental treatment that improves a medical condition. A societal benefit is the knowledge the study generates. Both are relevant, but they carry different weight. Direct participant benefits offset risks to the same person bearing them. Societal benefits alone can justify a study only when the risks to individual participants are reasonable relative to the importance of the expected knowledge.1eCFR. 45 CFR 46.111 – Criteria for IRB Approval of Research
Money paid to participants is not a benefit for purposes of this analysis. Federal guidance sorts participant payments into reimbursement for costs like travel and childcare, compensation for time and burden, appreciation gifts, and incentive payments beyond those categories, and none of them count when weighing benefits against risks. The reasoning is straightforward: if payment were treated as a benefit, a researcher could justify a dangerous study simply by paying enough. Large incentive payments raise a separate concern about undue influence, where the amount offered is high enough that participants stop weighing the risks carefully. The recommended response is a stronger consent process, including comprehension checks and time for reflection, rather than a hard cap on payment amounts.2U.S. Department of Health and Human Services. Attachment A – Addressing Ethical Concerns Offers of Payment to Research Participants
The Minimal Risk Threshold
Federal regulations define minimal risk as a probability and magnitude of harm no greater than what a person ordinarily encounters in daily life or during a routine physical or psychological exam.3eCFR. 45 CFR 46.102 – Definitions for Purposes of This Policy That threshold does a lot of work throughout the regulatory system. Studies at or below minimal risk can qualify for expedited review by the IRB chair or a designated experienced member rather than the full board. Studies above minimal risk go to the full board and face more rigorous safeguards. An expedited reviewer can approve a study or require modifications, but only the full board can disapprove one.4eCFR. 45 CFR 46.110 – Expedited Review Procedures
What an IRB Must Confirm Before Approval
The board’s authority comes from federal regulation. Under FDA rules and the Common Rule, an IRB can approve, require modifications to, or disapprove research involving human subjects.5U.S. Food and Drug Administration. Institutional Review Boards Frequently Asked Questions Before it can approve, it must find that all of the following are true:
- Risks to participants are minimized by sound research procedures, using diagnostic or treatment procedures already being performed where possible.
- Risks are reasonable in relation to anticipated benefits to participants and the importance of the knowledge the study is expected to produce.
- Selection of participants is equitable, with attention to whether the study targets people vulnerable to coercion or undue influence.
- Informed consent will be sought from each participant or their legally authorized representative.
- The research plan includes adequate provisions for monitoring data to protect participant safety when appropriate.
- The plan protects privacy and keeps data confidential when appropriate.
One detail that regularly surprises researchers: the IRB is specifically instructed not to consider the long-range effects of applying the knowledge gained from the research, such as potential policy changes, when it weighs risks. The analysis stays on what could happen to participants during the study itself.1eCFR. 45 CFR 46.111 – Criteria for IRB Approval of Research
Financial stakes on the researcher’s side can distort the balance the IRB is trying to strike, so investigators on federally funded projects must disclose significant financial interests that could affect the design, conduct, or reporting of the research. The National Institutes of Health sets the disclosure threshold at income above $5,000 from any single entity related to the researcher’s institutional responsibilities, and institutions must manage or eliminate identified conflicts before the work can proceed.6National Institutes of Health. Financial Conflict of Interest
Extra Weight for Vulnerable Participants
The calculation shifts when participants have a compromised ability to consent voluntarily. The Common Rule adds three subparts that layer extra protections onto the standard framework.
Children
Pediatric research falls into four approval categories based on risk level and the prospect of direct benefit. Studies presenting no more than minimal risk to children can be approved on that basis alone. Studies with greater than minimal risk are approvable only when the intervention holds out the prospect of directly benefiting the child, or when it will not benefit the individual child but is likely to yield generalizable knowledge about the child’s disorder. A fourth category covers studies that fit none of the above but present a reasonable opportunity to understand, prevent, or alleviate a serious problem affecting children’s health or welfare, and those require additional federal review beyond the local IRB.7eCFR. 45 CFR Part 46 Subpart D – Additional Protections for Children Involved as Subjects in Research
Prisoners
Prison environments create inherent pressure to participate, so the IRB reviewing such a study must include at least one prisoner or prisoner representative, and a majority of the board (excluding any prisoner members) must have no affiliation with the prison. The board must also confirm that any advantages of participation (better food, medical care, or living conditions) are not so significant that they impair a prisoner’s ability to weigh risks objectively, and that parole boards will not consider research participation in their decisions.8eCFR. 45 CFR Part 46 Subpart C – Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners as Subjects
Pregnant Women and Fetuses
Studies involving pregnant women require a dual analysis because two lives are at stake. The regulations permit such research only after preclinical studies on pregnant animals and clinical studies on nonpregnant women have been completed to assess potential risks. If an intervention offers no prospect of direct benefit to the woman or fetus, the risk to the fetus must be no greater than minimal, and the research must seek important biomedical knowledge that cannot be obtained any other way. Researchers involved in the study cannot have any role in decisions about pregnancy termination or neonatal viability.9eCFR. 45 CFR 46.204 – Research Involving Pregnant Women or Fetuses
How Risk Disclosure Reaches the Participant
The risk-benefit analysis feeds directly into the informed consent document. The consent form is not a formality. Federal regulations require it to communicate, in language the participant can understand:
- That the study involves research, along with its purpose, expected duration, and which procedures are experimental
- Reasonably foreseeable risks or discomforts
- Expected benefits to the participant or others
- Alternative procedures or treatments that might be available
- How confidentiality of records will be maintained
- Whether compensation or medical treatment is available if injury occurs, for studies above minimal risk
- Contact information for questions about the research, participant rights, and research-related injuries
- That participation is voluntary and can be withdrawn at any time without penalty
- Whether identifiers might be stripped from collected data or biospecimens and used in future research
Participants must have the chance to ask questions and to take whatever time they need to decide. The signature is valid only if given voluntarily, without coercion. The participant receives a copy of the signed document; the institution keeps the original for audit.
When the Analysis Gets Revisited
Approval is not the end of the risk-benefit analysis. Harms that emerge during the study can change the board’s original assessment, and researchers have ongoing reporting duties.
For drug studies under an investigational new drug application, investigators must report any serious adverse event to the sponsor immediately, which the FDA generally reads as within one calendar day. A serious adverse event is one that results in death, a life-threatening condition, hospitalization, persistent disability, or a birth defect. For medical device studies, investigators must report unanticipated adverse effects to both the sponsor and the IRB within 10 working days.11U.S. Food and Drug Administration. Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices
Beyond individual events, researchers and IRBs watch for “unanticipated problems” suggesting the study poses greater risk than originally recognized. These are events that are unexpected given the protocol, possibly related to participation, and indicative of more danger to participants than was previously known. Institutions must have written procedures for promptly reporting such problems to the IRB, institutional officials, the relevant agency head, and the Office for Human Research Protections.12eCFR. 45 CFR 46.108 – IRB Functions and Operations
When serious problems surface, the IRB can suspend or terminate approval. That power applies in two circumstances: the research is not being conducted in accordance with the board’s requirements, or the research has been associated with unexpected serious harm to participants. The board must issue a written statement of its reasons and promptly notify the investigator, institutional officials, and the relevant federal agency.13eCFR. 45 CFR 46.113 – Suspension or Termination of IRB Approval of Research It is the enforcement backstop that keeps the original risk-benefit balance honest once enrollment is underway.